Explore
Validate
LearnH00057016-M01
antibody from Novus Biologicals
Targeting: AKR1B10
AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [2]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00057016-M01 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00057016-M01, RRID:AB_536683
- Product name
- Mouse Monoclonal Aldo-keto Reductase 1B10/AKR1B10 Antibody
- Antibody type
- Monoclonal
- Description
- IgG purified. AKR1B10 - aldo-keto reductase family 1, member B10 (aldose reductase)
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report.
A physiological concentration of luteolin induces phase II drug-metabolizing enzymes through the ERK1/2 signaling pathway in HepG2 cells.
Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells.
AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
Quantification of the host response proteome after herpes simplex virus type 1 infection.
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Phadke G, Kaushal A, Tolan DR, Hahn K, Jensen T, Bjornstad P, Roncal-Jimenez C, Hernando AA, Lanaspa MA, Alexander MP, Kukla A, Johnson RJ
American journal of kidney diseases : the official journal of the National Kidney Foundation 2020 Jul;76(1):144-147
American journal of kidney diseases : the official journal of the National Kidney Foundation 2020 Jul;76(1):144-147
A physiological concentration of luteolin induces phase II drug-metabolizing enzymes through the ERK1/2 signaling pathway in HepG2 cells.
Kitakaze T, Makiyama A, Samukawa Y, Jiang S, Yamashita Y, Ashida H
Archives of biochemistry and biophysics 2019 Mar 15;663:151-159
Archives of biochemistry and biophysics 2019 Mar 15;663:151-159
Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells.
Park SH, Kim JH, Ko E, Kim JY, Park MJ, Kim MJ, Seo H, Li S, Lee JY
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018 May 29;:fj201800011R
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018 May 29;:fj201800011R
AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
Connor JP, Esbona K, Matkowskyj KA
Human pathology 2017 Dec;70:77-83
Human pathology 2017 Dec;70:77-83
Quantification of the host response proteome after herpes simplex virus type 1 infection.
Berard AR, Coombs KM, Severini A
Journal of proteome research 2015 May 1;14(5):2121-42
Journal of proteome research 2015 May 1;14(5):2121-42
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R, Yang GY
Human pathology 2014 Apr;45(4):834-43
Human pathology 2014 Apr;45(4):834-43
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
Moriguchi H, Zhang Y, Mihara M, Sato C
Scientific reports 2012;2:280
Scientific reports 2012;2:280
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.
Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern CD, Wardle FC, Flanagan AM
The Journal of pathology 2012 Nov;228(3):274-85
The Journal of pathology 2012 Nov;228(3):274-85
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Chung YT, Matkowskyj KA, Li H, Bai H, Zhang W, Tsao MS, Liao J, Yang GY
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 May;25(5):758-66
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 May;25(5):758-66
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J
Liver international : official journal of the International Association for the Study of the Liver 2011 Jul;31(6):810-6
Liver international : official journal of the International Association for the Study of the Liver 2011 Jul;31(6):810-6
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2518-28
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2518-28
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS, Grigliatti TA, Reid RE, Riggs KW
The Journal of pharmacology and experimental therapeutics 2010 Dec;335(3):533-45
The Journal of pharmacology and experimental therapeutics 2010 Dec;335(3):533-45
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Aldo-keto Reductase 1B10/AKR1B10 Antibody (1A6) [H00057016-M01] - Analysis of AKR1B10 expression in transfected 293T cell line by AKR1B10 monoclonal antibody (M01), clone 1A6.Lane 1: AKR1B10 transfected lysate(36 KDa).Lane 2: Non-transfected lysate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Aldo-keto Reductase 1B10/AKR1B10 Antibody (1A6) [H00057016-M01] - AKR1B10 monoclonal antibody (M01), clone 1A6 Analysis of AKR1B10 expression in HepG2.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- ELISA: Aldo-keto Reductase 1B10/AKR1B10 Antibody (1A6) [H00057016-M01] - Detection limit for recombinant GST tagged AKR1B10 is approximately 0.1ng/ml as a capture antibody.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Sandwich ELISA: Aldo-keto Reductase 1B10/AKR1B10 Antibody (1A6) [H00057016-M01] - Detection limit for recombinant GST tagged AKR1B10 is approximately 0.03ng/ml as a capture antibody.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunocytochemistry/Immunofluorescence: Aldo-keto Reductase 1B10/AKR1B10 Antibody (1A6) [H00057016-M01] - Analysis of monoclonal antibody to AKR1B10 on HeLa cell. Antibody concentration 10 ug/ml.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: Aldo-keto Reductase 1B10/AKR1B10 Antibody (1A6) [H00057016-M01] - Analysis of monoclonal antibody to AKR1B10 on formalin-fixed paraffin-embedded human colon. Antibody concentration 3 ug/ml.
